LGND - CIK 0000886163
LIGAND PHARMACEUTICALS INC (LGND) reported net income of $124.45M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | $124.45M | +3186.6% |
| FY 2024 | -$4.03M | -107.7% |
| FY 2023 | $52.15M | +256.3% |
| FY 2022 | -$33.36M | -158.4% |
| FY 2021 | $57.14M | +2014.2% |
| FY 2020 | -$2.98M | -100.5% |
| FY 2019 | $629.30M | +339.1% |
| FY 2018 | $143.32M | +1041.5% |
| FY 2017 |
LIGAND PHARMACEUTICALS INC (LGND) reported net income of $124.45M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, LIGAND PHARMACEUTICALS INC's net income grew from $9.71M to $124.45M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $12.56M |
| +867.5% |
| FY 2016 | -$1.64M | -100.7% |
| FY 2015 | $229.82M | +1811.4% |
| FY 2014 | $12.02M | +5.3% |
| FY 2013 | $11.42M | +2267.0% |
| FY 2012 | -$527.00K | -105.4% |
| FY 2011 | $9.71M | - |